Amicus Therapeutics, Inc. (0HF9.L)
USD 7.12
(-0.14%)
USD 7.12
(-0.14%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -73.49 Million USD | 64.05% |
| 2022 | -204.42 Million USD | -2.25% |
| 2021 | -199.92 Million USD | 18.02% |
| 2020 | -243.85 Million USD | 18.92% |
| 2019 | -300.74 Million USD | 8.53% |
| 2018 | -328.77 Million USD | 25.61% |
| 2017 | -441.98 Million USD | -143.0% |
| 2016 | -181.89 Million USD | -39.45% |
| 2015 | -130.43 Million USD | -89.86% |
| 2014 | -68.7 Million USD | -7.04% |
| 2013 | -64.18 Million USD | -21.25% |
| 2012 | -52.93 Million USD | -4.02% |
| 2011 | -50.88 Million USD | 8.87% |
| 2010 | -55.83 Million USD | -659.7% |
| 2009 | -7.35 Million USD | 83.28% |
| 2008 | -43.95 Million USD | 4.04% |
| 2007 | -45.8 Million USD | 2.25% |
| 2006 | -46.85 Million USD | -124.95% |
| 2005 | -20.83 Million USD | -136.53% |
| 2004 | -8.8 Million USD | -33.44% |
| 2003 | -6.6 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 14.96 Million USD | 169.05% |
| 2024 Q1 | -21.67 Million USD | -487.11% |
| 2023 Q4 | -3.69 Million USD | 78.31% |
| 2023 Q1 | -37.38 Million USD | 8.24% |
| 2023 FY | -73.49 Million USD | 64.05% |
| 2023 Q2 | -18.86 Million USD | 49.55% |
| 2023 Q3 | -17.02 Million USD | 9.74% |
| 2022 Q4 | -40.74 Million USD | -22.45% |
| 2022 FY | -204.42 Million USD | -2.25% |
| 2022 Q1 | -69.91 Million USD | 3.1% |
| 2022 Q2 | -60.61 Million USD | 13.3% |
| 2022 Q3 | -33.27 Million USD | 45.11% |
| 2021 Q2 | -38.83 Million USD | 26.8% |
| 2021 Q4 | -72.14 Million USD | -70.16% |
| 2021 FY | -199.92 Million USD | 18.02% |
| 2021 Q1 | -53.05 Million USD | 18.17% |
| 2021 Q3 | -42.39 Million USD | -9.18% |
| 2020 Q3 | -52.76 Million USD | -2.76% |
| 2020 Q1 | -78.05 Million USD | 12.32% |
| 2020 Q2 | -51.34 Million USD | 34.22% |
| 2020 FY | -243.85 Million USD | 18.92% |
| 2020 Q4 | -64.83 Million USD | -22.88% |
| 2019 Q2 | -76.43 Million USD | 5.97% |
| 2019 Q4 | -89.02 Million USD | -55.35% |
| 2019 Q3 | -57.3 Million USD | 25.02% |
| 2019 Q1 | -81.27 Million USD | -16.98% |
| 2019 FY | -300.74 Million USD | 8.53% |
| 2018 Q2 | -46.93 Million USD | 16.47% |
| 2018 Q4 | -69.48 Million USD | 55.51% |
| 2018 FY | -328.77 Million USD | 25.61% |
| 2018 Q1 | -56.18 Million USD | 16.99% |
| 2018 Q3 | -156.18 Million USD | -232.79% |
| 2017 Q1 | -52.01 Million USD | -14.55% |
| 2017 FY | -441.98 Million USD | -143.0% |
| 2017 Q4 | -67.67 Million USD | 75.41% |
| 2017 Q3 | -275.23 Million USD | -484.84% |
| 2017 Q2 | -47.06 Million USD | 9.52% |
| 2016 Q2 | -48.54 Million USD | -12.89% |
| 2016 FY | -181.89 Million USD | -39.45% |
| 2016 Q4 | -45.4 Million USD | -1.04% |
| 2016 Q3 | -44.94 Million USD | 7.42% |
| 2016 Q1 | -43 Million USD | -3.89% |
| 2015 FY | -130.43 Million USD | -89.86% |
| 2015 Q4 | -41.39 Million USD | -8.79% |
| 2015 Q3 | -38.04 Million USD | -41.21% |
| 2015 Q2 | -26.94 Million USD | -11.99% |
| 2015 Q1 | -24.05 Million USD | -9.37% |
| 2014 Q2 | -14.26 Million USD | 8.67% |
| 2014 Q3 | -16.81 Million USD | -17.87% |
| 2014 Q1 | -15.62 Million USD | 1.07% |
| 2014 FY | -68.7 Million USD | -7.04% |
| 2014 Q4 | -21.99 Million USD | -30.81% |
| 2013 Q2 | -16 Million USD | 7.22% |
| 2013 Q4 | -15.79 Million USD | -4.33% |
| 2013 Q1 | -17.25 Million USD | -8.34% |
| 2013 Q3 | -15.13 Million USD | 5.44% |
| 2013 FY | -64.18 Million USD | -21.25% |
| 2012 Q2 | -9.34 Million USD | 13.01% |
| 2012 Q4 | -15.92 Million USD | 5.87% |
| 2012 Q3 | -16.91 Million USD | -80.98% |
| 2012 Q1 | -10.74 Million USD | 17.54% |
| 2012 FY | -52.93 Million USD | -4.02% |
| 2011 Q4 | -13.03 Million USD | 0.79% |
| 2011 Q3 | -13.13 Million USD | 10.8% |
| 2011 Q1 | -9.99 Million USD | 39.53% |
| 2011 Q2 | -14.72 Million USD | -47.25% |
| 2011 FY | -50.88 Million USD | 8.87% |
| 2010 Q4 | -16.53 Million USD | -24.66% |
| 2010 FY | -55.83 Million USD | -659.7% |
| 2010 Q3 | -13.26 Million USD | -4.56% |
| 2010 Q2 | -12.68 Million USD | 4.97% |
| 2010 Q1 | -13.35 Million USD | -140.53% |
| 2009 FY | -7.35 Million USD | 83.28% |
| 2009 Q4 | 32.94 Million USD | 344.49% |
| 2009 Q3 | -13.47 Million USD | 2.72% |
| 2009 Q2 | -13.85 Million USD | -6.8% |
| 2009 Q1 | -12.96 Million USD | 12.83% |
| 2008 Q1 | -9.28 Million USD | 31.11% |
| 2008 FY | -43.95 Million USD | 4.04% |
| 2008 Q3 | -9.3 Million USD | 11.35% |
| 2008 Q2 | -10.49 Million USD | -12.95% |
| 2008 Q4 | -14.87 Million USD | -59.97% |
| 2007 Q3 | -11.8 Million USD | -14.8% |
| 2007 Q1 | -10.23 Million USD | 11.69% |
| 2007 Q4 | -13.48 Million USD | -14.2% |
| 2007 FY | -45.8 Million USD | 2.25% |
| 2007 Q2 | -10.28 Million USD | -0.51% |
| 2006 FY | -46.85 Million USD | -124.95% |
| 2006 Q2 | -11.58 Million USD | 0.0% |
| 2006 Q1 | -11.58 Million USD | -132.05% |
| 2006 Q4 | -11.58 Million USD | 0.0% |
| 2006 Q3 | -11.58 Million USD | 0.0% |
| 2005 Q1 | -4.99 Million USD | 0.0% |
| 2005 Q3 | -4.99 Million USD | 0.0% |
| 2005 Q2 | -4.99 Million USD | 0.0% |
| 2005 Q4 | -4.99 Million USD | 0.0% |
| 2005 FY | -20.83 Million USD | -136.53% |
| 2004 FY | -8.8 Million USD | -33.44% |
| 2003 FY | -6.6 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 99.478% |
| uniQure N.V. | -282.87 Million USD | 74.019% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 24.511% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 81.227% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 73.372% |
| bluebird bio, Inc. | -244.26 Million USD | 69.912% |
| Blueprint Medicines Corporation | -486.27 Million USD | 84.886% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 39.509% |
| Imunon, Inc. | -21.03 Million USD | -249.465% |
| Adicet Bio, Inc. | -152.03 Million USD | 51.661% |
| Dynavax Technologies Corporation | -37.02 Million USD | -98.482% |
| Editas Medicine, Inc. | -169.18 Million USD | 56.559% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 33.559% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 84.042% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 103.717% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 106.759% |
| Myriad Genetics, Inc. | -123.7 Million USD | 40.587% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 129.292% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 72.559% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -1294.838% |
| Verastem, Inc. | -92.08 Million USD | 20.188% |
| Waters Corporation | 817.67 Million USD | 108.988% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 101.706% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 101.071% |
| Biogen Inc. | 1.29 Billion USD | 105.667% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 27.109% |
| Perrigo Company plc | 151.9 Million USD | 148.383% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -64.538% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 52.756% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -52.477% |
| Geron Corporation | -193.94 Million USD | 62.106% |
| Illumina, Inc. | -1.06 Billion USD | 93.125% |
| Homology Medicines, Inc. | -48.25 Million USD | -52.303% |
| Nektar Therapeutics | -137.42 Million USD | 46.521% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -63.04% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 137.798% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 73.178% |
| Evolus, Inc. | -49.23 Million USD | -49.278% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 101.816% |
| FibroGen, Inc. | -281.81 Million USD | 73.921% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 105.444% |
| OPKO Health, Inc. | -157.02 Million USD | 53.195% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 73.954% |
| Exelixis, Inc. | 170.88 Million USD | 143.008% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -31.814% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 85.737% |
| Zoetis Inc. | 3.06 Billion USD | 102.395% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 68.298% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -87.71% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 79.223% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 168.505% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 121.771% |
| Insmed Incorporated | -709.62 Million USD | 89.643% |
| TG Therapeutics, Inc. | 20.63 Million USD | 456.196% |
| Incyte Corporation | 620.52 Million USD | 111.844% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 89.882% |